

B1
cont
4. ✓ (amended) A method as set forth in claim 1 in which the medicament contains 0.003 to 0.5% (weight/weight) of azelastine or an amount of a physiologically acceptable salt of azelastine which contains 0.003 to 0.5% (weight/weight) azelastine.

B2
12. ✓ (amended) A method for the treatment of a patient suffering from allergy-related, or vasomotor or rhino-related colds or symptoms which comprises applying directly to the patient's nasal tissues or to the conjunctival sac of the patient's eye a medicament which contains a member [of] selected from the group consisting of azelastine and its physiologically acceptable salts.

REMARKS

The applicant respectfully requests reconsideration.

n
p
r
k
The claims have been amended in several respects to deal with the rejections under 35 U.S.C. 112. Thus, for example, the language introducing the Markush groups in claims 1 and 12 has been changed to the form suggested by the Examiner. In claims 2-4, the amounts of the physiologically acceptable salts has been described. This amendment is based on the disclosure on page 5, lines 6-8 from the bottom.

However, applicants submit that the phrase "predetermined amount" in claim 15 is not indefinite. The precise amount which is released when the atomizing container is actuated, of course, depends on two factors. First, it depends on the concentration of azelastine in the liquid in the aerosol container. Secondly, it depends on the amount of liquid which is released when the aerosol container is actuated. The two factors are selected so that the patient receives the dosage which is desired. The word